Allergan, FDA To Meet On Tazoral NDA Deficiencies By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
The meeting follows a Sept. 24 "not approvable" letter for the psoriasis treatment tazarotene. Allergan says the meeting is needed to provide insight into trial design for a non-inferiority trial.
You may also be interested in...
Allergan To Discuss Tazoral Psoriasis Non-Inferiority Study With FDA
FDA deems oral tazarotene "not approvable." In addition to a non-inferiority study, Allergan must develop an "acceptable" risk management program and resolve manufacturing problems.
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.
Astellas Ends Aczone Acne Treatment Collaboration Agreement With QLT
QLT now has worldwide marketing rights to the topical acne treatment. Astellas believes labeling proposed by FDA will limit the market profile for Aczone, the company said. Aczone’s user fee deadline is July 7.